

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**BEIJING TONG REN TANG CHINESE MEDICINE COMPANY LIMITED**  
**北京同仁堂國藥有限公司**  
*(Incorporated in Hong Kong with limited liability)*  
**(Stock Code: 3613)**

**APPOINTMENT OF EXECUTIVE DIRECTOR AND  
MEMBER OF COMPETITION EXECUTIVE COMMITTEE**

**APPOINTMENT OF EXECUTIVE DIRECTOR AND MEMBER OF COMPETITION  
EXECUTIVE COMMITTEE**

The board of directors (the “**Board**”) of Beijing Tong Ren Tang Chinese Medicine Company Limited (the “**Company**”) is pleased to announce that Mr. Yu Jin (“**Mr. Yu**”), the chief executive officer of the Company, has been appointed as an executive director and a member of competition executive committee of the Company with effect from 20 October 2023.

The biographical details of Mr. Yu are set out as follows:

**Yu Jin**, aged 54, has been appointed as the chief executive officer of the Company on 19 April 2023. Mr. Yu has more than 30 years of experience in medical and pharmaceutical industry. Mr. Yu was an assistant to the chairman of the board of directors in Tianda Pharmaceuticals Limited (stock code: 0455) from 2022 to February 2023 and served as the managing director in Beiyu Medical Device (Shanghai) Co., Ltd. from 2016 to 2022. Mr. Yu held senior positions such as general manager of the PRC region in different well-known multinational medical and pharmaceutical companies including Abbott’s Diabetes Care Division, Johnson & Johnson Vision, Gambro and BSN Medical. Mr. Yu obtained a bachelor’s degree in industrial foreign trading from Guangdong Institute of Technology (now known as Guangdong University of Technology) in 1991 and obtained EMBA degree from China Europe International Business School in 2011.

Mr. Yu shall hold office until the next following annual general meeting of the Company and if re-elected by shareholders of the Company (the “**Shareholders**”) thereat, will be subject to retirement by rotation and re-election at annual general meeting of the Company at least once every three years in accordance with the articles of association of the Company. A service contract (the “**Contract**”) was entered into between the Company and Mr. Yu on 20 October 2023 for a period of three years. Pursuant to the Contract, Mr. Yu will not receive any director’s fee as an executive director of the Company.

As at the date of this announcement, Mr. Yu does not have any interest or short position in the shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

As at the date of this announcement, save as disclosed above, Mr. Yu has not held any directorship in any Hong Kong or overseas listed companies in the last three years. Mr. Yu does not have any relationship with any director, senior management or substantial or controlling Shareholder(s) (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of the Hong Kong Limited (the “**Listing Rules**”)) of the Company nor does he hold any other position with the Company or any of its subsidiaries.

Save as disclosed above, Mr. Yu has confirmed that there is no other information relating to him that is required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters which need to be brought to the attention of the Shareholders in connection with the aforesaid appointment.

The Board would like to extend its warmest welcome to Mr. Yu for joining the Board.

By order of the Board  
**Beijing Tong Ren Tang**  
**Chinese Medicine Company Limited**  
**Chen Fei**  
*Executive Director*

Hong Kong, 20 October 2023

As at the date of this announcement, the composition of the Board is as follows:

***Executive Directors:***

Mr. Yu Jin  
Mr. Chen Fei

***Non-executive Director:***

Ms. Feng Li

***Independent Non-executive Directors:***

Mr. Tsang Yok Sing, Jasper  
Mr. Xu Hong Xi  
Mr. Chan Ngai Chi